Electronic Journal of General Medicine

Declaration of Conflict of Interest: No conflict of interest is declared by author(s).

• Pickham D, Helfenbein E, Shinn JA. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: Results of the QT in Practice (QTIP) Study Critical Care Medicine. 2012;2(40):394-9. https://doi.org/10.1097/CCM.0b013e318232db4a.
• Isbister GK, Page CB. Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice. British journal of clinical pharmacology. 2013;76(1):48-57. https://doi.org/10.1111/bcp.12040.
• Schwartz PJ, Spazzolini C, Crotti L. The Jervell and Lange-Nielsen Sundrome: natural history, molecular basis and clinical outcome. Circulation. 2006;113:783-90. https://doi.org/10.1161/CIRCULATIONAHA.105.592899.
• Combined List of Drugs that Prolong QT and/or cause Torsades de Pointes (TdP). Retrieved on 16 Feb. 2016 from https://crediblemeds.org/healthcare-providers/drug-list/.
• Woosley R. Drugs that prolong the QTc interval and/or induce torsade de pointes. Retrieved on 3 Mar. 2015 from http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs.
• Iannini PB, Circiumaru I, Byazrova E, Doddamani S, Kramer H. QTc prolongation associated with levofloxacin [abstr]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada. Washington: American Society for Microbiology. 2000.
• Meyer FP. QT-Intervall-Verlangerung durch Pharmaka. Rardiotoxizitat von Arzneimitteln. Mschr Kinderheilk. 2004;25:967-73.
• Owens RC. Risk Assessment for Antimicrobial Agent-Induced QTc Interval Prolongation and Torsades de Pointes. Pharmacotherapy. 2001;21:310-19. https://doi.org/10.1592/phco.21.3.301.34206.
• Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation:implications for drug approval and labelling. Drug Saf. 2001;24:323–51. https://doi.org/10.2165/00002018-200124050-00001.
• Arsentyeva RKh. Long QT syndrome. The Bulletin of Contemporary Clinical Medicine. 2012;5(3):129-138. https://doi.org/10.20969/VSKM.2012.5(3).69-73.
• Camn AJ, Lusher TF, Serruys PW. The ESC Textbook of Cardiovascular Medicine. Moscow: Geotarmedia. 2011.
• Sychev DA. Polipragmazija v klinicheskoj praktike: problema i reshenija. St.Patersburg: COP «Professija». 2016.
• Sychev DA, Bordovsky SP, Danilina KS, Ilyina, ES. Inappropriate prescribing in older people: STOPP/START criteria. Clin. Pharmacol. Ther. 2016;25(1):76-81.
• Sychev DA, Otdelenov VA. Mezhlekarstvennye vzaimodejstvija v praktike internista: vzgljad klinicheskogo farmakologa. Spravochnik poliklinicheskogo vracha. 2014;12:18-21.
• Sychev DA, Sosnovsky EE, Orekhov RE, Bordovsky SP. Contemporary methods of dealing with polypharmacy in elderly and senile patients. Siberian Medical Review. 2016;2(98):352-367. https://doi.org/10.20333/25000136-2016-2-13-21.
• Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41-57. https://doi.org/10.2165/00003088-200038010-00003.
• Ismagilov AD, Shich EV, Sizova ZhM, Dorofeeva MN, Tyajelnikov AA. Clinical and pharmacological aspects of drugs administration that influence on qt interval in elderly patients. Clinical Gerontology. 2016;4(22):37-45.
• Taizhanova DZ, Romaniuk YL. Syndrome of the QT interval prolongation: diagnosis and treatment. International Journal of Applied And Fundamental Research. 2015;3:218-21.
• Furman NV, Shmatova SS. Problems and prospects of intermediary metabolism correction in patients with vascular comorbidity. Rational Pharmacotherapy in Cardiology. 2013;9(3):311-315. https://doi.org/10.20996/1819-6446-2013-9-3-311-315.
• Shikh EV, Ismagilov AD, Dorofeeva MN, Sizova ZhM. Modern aspects of the safe use of extension QT interval medicines. Anesthesiology and Intensive Care. 2016;61(5):386-90. https://doi.org/10.18821/0201-7563-2016-61-5-386-390.
• Shikh EV, Fomin ЕV, Shumyantseva VV, Bulko TV. Combined therapy of elderly patients with regard to drugs metabolis. Clinical Gerontology. 2012;3-4:54-8.
• Kao LW, Furbee RB. Drug-induced q-T prolongation. Med. Clin. North. Am. 2005;89(6):1125–44. https://doi.org/10.1016/j.mcna.2005.06.003.
• Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760–81. https://doi.org/10.1124/pr.110.003723.
• Vatutin NT, Kalinkina NV, Shevelyok AN. The Role of T-Wave Alternans in Prognosis of Risk of Sudden Cardiac Death. Kardiologiia. 2009;11:46.
• Fomin EV, Baychorov IH, Shih EV, Sizova ZhM. Preclinical Investigation of Pharmaceuticals Impact against Cytochrome P450 Activity and Prognosis of Substrate Affinity as Means for Providing Substrate Therapy Safety. Antibiotics and Chemotherapy. 2013;7:34-9.

Vancouver

Ismagilov AD, Shikh EV, Sizova ZM, Shindryaeva NN. Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate. ELECTRON J GEN MED. 2018;15(4):em68. https://doi.org/10.29333/ejgm/93166

APA

Ismagilov, A. D., Shikh, E. V., Sizova, Z. M., & Shindryaeva, N. N. (2018). Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate. Electronic Journal of General Medicine, 15(4), em68. https://doi.org/10.29333/ejgm/93166

AMA

Ismagilov AD, Shikh EV, Sizova ZM, Shindryaeva NN. Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate. ELECTRON J GEN MED. 2018;15(4), em68. https://doi.org/10.29333/ejgm/93166

Chicago

Ismagilov, Artur D., Evgeniya V. Shikh, Zhanna M. Sizova, and Natalya N. Shindryaeva. "Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate". Electronic Journal of General Medicine 2018 15 no. 4 (2018): em68. https://doi.org/10.29333/ejgm/93166

Harvard

Ismagilov, A. D., Shikh, E. V., Sizova, Z. M., and Shindryaeva, N. N. (2018). Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate. Electronic Journal of General Medicine, 15(4), em68. https://doi.org/10.29333/ejgm/93166

MLA

Ismagilov, Artur D. et al. "Prolongation of the QT interval in patients with coronary heart disease as consequence of drug-drug interactions on metabolic rate". Electronic Journal of General Medicine, vol. 15, no. 4, 2018, em68. https://doi.org/10.29333/ejgm/93166